NCT02187588已完成2 期
Short Term Double Blind Randomised Controlled Study to Assess the Kinetic of the Analgesic Effect and the Tolerability of Eschscholtzia Californica 500 mg and 1000 mg Versus Ibuprofen 200 mg and Placebo in the Treatment of Pain After Surgery of the Third Molar
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
- 主要终点
- VAS-SPID - summed pain intensity differences (SPID) on a VAS (Visual Analogue Scale)
研究概览
简要总结
Study to determine the kinetic of the analgesic effect of 500 mg and 1000 mg of Eschscholtzia Californica per os and placebo in patients undergoing dental surgery over an observation period of 6 hours. In a secondary analysis, kinetic of analgesic effect comparison between Eschscholtzia californica 500 mg, 1000 mg and Ibuprofen 200 mg
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female above 18 or below 61 years old
- •Patient having to undergo a third molar removal from the lower jaw under local troncular anesthesia (articaine + adrenaline)
- •Type of inclusion of the molar:
- •Molar in the sub-mucosa: Type II
- •Molar partially impacted in the bone: Type III
- •Patient suffering from at least moderate to severe pain after surgical removal of an impacted third molar, defined by a 4 point verbal rating scale
- •Patient's informed consent in accordance with the French legislation
- •Patient affiliated to the Social Security System
排除标准
- •Pregnant or nursing female or female of childbearing potential not using a medically approved method of contraception like oral contraception or intrauterine contraceptive device
- •Patient with any pathology inducing a chronic pain
- •Patient having taken any drug with analgesic properties in the 24 hours previous to the administration of the study drug
- •Patient with concomitant administration of other Non-Steroid Anti-Inflammatory Drug(s) (NSAIDs) or analgesic agents
- •Patients treated by an antibiotic different from those required for the dental surgery which administration is started 48 hours prior to the tooth removal
- •Patient with significant peri-operative complication judged by the investigator
- •Patient with anti-coagulants concomitant treatment (including heparin)
- •Patient with severe hepatic or renal insufficiency which judged to be regarded as clinically relevant by the investigator or any known clinically significant disease which may induce a risk for the patient in participating to the trial
- •Patient with mental disturbance
- •Patient with non controlled diabetes
- •Patient with acute infections
- •Patient with respiratory insufficiency, asthma
- •Patient unable to comply with the protocol
- •Patient having taken part in a clinical trial in the past month or already participating in another trial
- •Patient deprived of their freedom by a judicial or administrative decision
- •Adults under guardianship
- •Persons hospitalized in medical or social establishments
- •Patients in emergency situation
- •Patient with a known or suspected hypersensitivity to the trial medication, to Ibuprofen, Paracetamol, anesthetic used (articaine, adrenaline), to the preventive antibiotic treatment (penicillin, macrolides)
- •Post study exclusion period: the patient will not be able to participate in any other trial for a period of two weeks after the end of this trial
研究组 & 干预措施
Eschscholtzia Californica - low dose
Experimental
干预措施: Eschscholtzia Californica - low dose (Drug)
Eschscholtzia Californica - low dose
Experimental
干预措施: Eschscholtzia Californica - low dose Placebo (Drug)
Eschscholtzia Californica - low dose
Experimental
干预措施: Ibuprofen Placebo (Drug)
Eschscholtzia Californica - high dose
Experimental
干预措施: Eschscholtzia Californica - high dose (Drug)
Eschscholtzia Californica - high dose
Experimental
干预措施: Ibuprofen Placebo (Drug)
Ibuprofen
Active Comparator
干预措施: Ibuprofen (Drug)
Ibuprofen
Active Comparator
干预措施: Eschscholtzia Californica - high dose Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Eschscholtzia Californica - high dose Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Ibuprofen Placebo (Drug)
结局指标
主要结局
VAS-SPID - summed pain intensity differences (SPID) on a VAS (Visual Analogue Scale)
时间窗: Baseline, up to 6 hours after drug intake
次要结局
- Total pain relief on a 5-point VRS(up to 6 hours after drug intake)
- Pain intensity differences (PID) on a VAS(Baseline, up to 6 hours after drug intake)
- Pain intensity difference in the groups on a VAS(Baseline, 2 hours after drug intake)
- Time point for maximum pain intensity difference on VAS(Baseline, up to 6 hours after drug intake)
- Number of patients with a pain decrease of at least 50 % over the all period of observation on a VAS(Baseline, up to 6 hours after drug intake)
- Pain relief at each observed time points on a 5-point verbal rating scale (VRS)(up to 6 hours after drug intake)
- Global efficacy assessment on a 4-points VRS(2 and 6 hours after drug intake, day 7)
- Number of patients requiring a rescue medication(Day 1)
- Number of patients with adverse events(up to 9 days after treatment)
- Assessment of tolerability by investigator on a 4-point VRS(6 hours after drug intake, day 7)
- Assessment of tolerability by subject on a 4-point VRS(6 hours after drug intake, day 7)
研究者
相似试验
终止
3 期
Efficacy and Safety of Eschscholtzia Californica in Treating Primary InsomniaSleep Initiation and Maintenance DisordersNCT02183233Boehringer Ingelheim49
尚未招募
不适用
A study to compare and evauate the analgesic effect of amitriptyline and pregabalin in acute phase of herpes zosterCTRI/2018/06/014475Department of anaesthesiology and critical care
已完成
3 期
A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINVPainNauseaVomitingNCT03657810Charleston Laboratories, Inc349
已完成
4 期
Evaluation of the Analgesy With Emla and/or Nitrous Oxide in Pediatric Patients for Lumbar PunctureNon Hodgkin LymphomaLeukemiaNCT00808171Federal University of Minas Gerais52
已完成
2 期
Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third MolarPainNCT02183051Boehringer Ingelheim381